A,In reference to M79’s post we are talking about 2 different...

A,
In reference to M79’s post we are talking about 2 different applications:

My best view/interpretation is as follows:

The July 11 MSB ASX P3 announcement is about Mesoblasts MPC technology and how it can work for BONE MARROW TRANSPLANT. THE MPC technology aims to lower(or prevent) the risk of GVHD from occurring when a BM transplant occurs

Where as OSIRIS Prochymal is a treatment for Acute GVHD when it arises - this oocurs in approximately 50% of all patients who receive a hematopoietic stem cell transplant (HSCT).

Extract from July 11 ASX announcement as follows:
...."Mesoblasts proprietary adult stem cells expand hematopoietic precursor cells in umbilical cord blood 40-fold, enabling rapid bone marrow reconstitution with lowered risk of life-threatening Graft Versus Host Disease (GVHD)

• Melbourne, Australia; 7 July 2011: Global regenerative medicine company Mesoblast Limited (ASX:MSB; OTC ADR: MBLTY) today announced that it has received clearance from the United States Food and Drug Administration (FDA) to begin a Phase 3 clinical trial for bone marrow regeneration in patients with blood cancers.
The Phase 3 trial will aim to reproduce the positive pilot trial results seen at the University of Texas MD Anderson Cancer, where accelerated neutrophil and platelet recoveries, together with excellent 100-day patient survival and low GVHD rates, occurred in patients receiving partially mismatched hematopoietic cells from umbilical cord blood expanded by Mesoblasts proprietary allogeneic or off-the-shelf mesenchymal precursor cells (MPCs).
The P3 trial is currently ongoing...."

The indication that the 2 trials are separate can be referenced back to Page 27 of the MSB's half yearly update on 26/2/2014

Programs in oncology conditions associated with bone:
Commercial Ready (this is Osiris MSC technology)
Pediatric GVHD (Canada & New Zealand) using MSCs

Phase 3 (this is MSB’s MPC technology)
Cord blood expansion for hematological malignancies using MPCs


Yes – I agree that the SP is tiring for all ...no question about that .

Teva P3 shenanigans ; US Biotech correction and no news on Japan plans - yet ( not just GVHD but around the MPC technology applications) have not helped.

Perfect for the manips to continue to have a field day.

The above is all in IMO . Please DYOR.